Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00465803 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT00465803: Completed Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Alcon Research.
NCT00465803 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Alcon Research. The registered enrollment target is 81 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00465803, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
Primary Outcome
Patient compliance will be measured with a dosing aid that records time and date of study drug administration
Conditions Studied
Interventions
- DRUG Travoprost 0.004%/timolol 0.5% ophthalmic solution
- DRUG Travoprost ophthalmic solution, 0.004%
- DRUG Timolol maleate ophthalmic solution, 0.5%
Study Locations (1)
Washington
- Seattle - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-03 |
| Phase | Phase 3 |
What the finished NCT00465803 record still lists
NCT00465803 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Travoprost 0.004%/timolol 0.5% ophthalmic solution is the first listed.
NCT00465803 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00465803 about?
NCT00465803 is a clinical study titled "A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension". The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00465803?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2007-03.
What conditions does trial NCT00465803 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT00465803?
The interventions under investigation include: Travoprost 0.004%/timolol 0.5% ophthalmic solution (DRUG), Travoprost ophthalmic solution, 0.004% (DRUG), Timolol maleate ophthalmic solution, 0.5% (DRUG).
Who is sponsoring clinical trial NCT00465803?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00465803 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00465803's enrollment target sits among peer trials
81 39th of 54 higher than 16 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia